solo para uso en investigación

Pirfenidone TGF-β inhibitor

Cat. No.: S2907

Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.
Pirfenidone TGF-beta/Smad inhibitor Chemical Structure

Estructura química

Peso molecular: 185.22

Saltar a

Control de calidad (Quality Control)

Lote: Pureza: 99.98%
99.98

Cultivo celular, tratamiento y concentración de trabajo
(Cell Culture, Treatment & Working Concentration)

Líneas celulares Tipo de ensayo Concentración Tiempo de incubación Formulación Descripción de la actividad PMID
HFL1 cells Function assay 48 h Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay, IC50 = 0.71 μM. 26896707
LNCaP Cell growth assay 0, 0.1, 0.3 mg/ml 3 days PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml 30621175
PC-3 Cell growth assay 0, 0.1, 0.3 mg/ml 3 days PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml 30621175
E9 Cell growth assay 0, 0.1, 0.3 mg/ml 3 days PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml 30621175
F10 Cell growth assay 0, 0.1, 0.3 mg/ml 3 days PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml 30621175
AIDL Cell growth assay 0, 0.1, 0.3 mg/ml 3 days PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml 30621175
human intestinal fibroblasts (HIFs) Function assay 1 h PFD inhibits HIFs differentiation and the collagen deposition induced by TGF-β1. 30152848
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad (Chemical Information, Storage & Stability)

Peso molecular 185.22 Fórmula

C12H11NO

Almacenamiento (Desde la fecha de recepción)
Nº CAS 53179-13-8 Descargar SDF Almacenamiento de soluciones madre

Sinónimos S-7701, AMR-69 Smiles CC1=CN(C(=O)C=C1)C2=CC=CC=C2

Solubilidad (Solubility)

In vitro
Lote:

DMSO : 37 mg/mL (199.76 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Ethanol : 37 mg/mL

Water : Insoluble

Calculadora de Molaridad

Masa Concentración Volumen Peso molecular
Calculadora de Dilución Calculadora de Peso Molecular

In vivo
Lote:

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

mg/kg g μL

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción (Mechanism of Action)

Targets/IC50/Ki
TGF-β
(Cell-free assay)
In vitro

Pirfenidone (< 300 μg/mL) suppresses the proinflammatory cytokine tumor necrosis factor-α (TNF-α) by a translational mechanism in RAW264.7 cells, which is independent of activation of the mitogen-activated protain kinase (MAPK) 2, p38 MAP kinase, and c-Jun N-terminal kinase (JNK).

This compound (< 10 mM) leads to reduced glioma cell density in concentration-dependent manner in LN-18, T98G, LNT-229 and LN-308 cell lines. It (< 5 mM) reduces TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. This chemical (< 8.3 mM) inhibits the activity of recombinant furin and downregulates the expression of MMP-11 in a dose-dependent manner in LN-308 cells.

In vivo

Pirfenidone (250 mg/kg) potently inhibits the production of the proinflammatory cytokines, TNF-alpha, interferon-gamma, and interleukin-6, but enhances the production of the anti-inflammatory cytokine, interleukin-10, in mice.

This compound (250 mg/kg/day) ameliorates cyclosporine-induced fibrosis by about 50% and decreases TGF-beta1 protein expression by 80% in Sprague-Dawley rats receiving a low-salt diet.

It (400 mg/kg/day) inhibits heat shock protein 47-positive cells and myofibroblasts, the principal cells responsible for the accumulation and deposition of extracellular matrix seen in pulmonary fibrosis in ICR mice intravenously injected with bleomycin.

This chemical (0.5%, liquid diet) treatment reduces the degree of liver injury in rats, as determined by alanine aminotransferase values and necro-inflammatory score, which is associated with reduced hepatic stellate cells proliferation and collagen deposition. This compound (0.5%, liquid diet) administration downregulates dimethylnitrosamine induced transcripts levels of procollagen alpha1(I), TIMP-1 and MMP-2 by 50-60% in rats, and this is associated with a 70% reduction in collagen deposition.

Referencias
  • [4] https://pubmed.ncbi.nlm.nih.gov/15293605/
  • [5] https://pubmed.ncbi.nlm.nih.gov/15571005/
  • [6] https://pubmed.ncbi.nlm.nih.gov/35130111/

Aplicaciones (Applications)

Métodos Biomarcadores Imágenes PMID
Immunofluorescence α-SMA SMAD4 / SMAD2 / SMAD3 F-actin / β-catenin / Vimentin
S2907-IF1
22132230

Información del ensayo clínico (Clinical Trial Information)

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT Reclutamiento Condiciones Patrocinador/Colaboradores Fecha de inicio Fases
NCT05676112 Withdrawn
Pulmonary Fibrosis
Boehringer Ingelheim|China-Japan Friendship Hospital
December 29 2023 --
NCT06070610 Completed
Healthy
Boehringer Ingelheim
November 8 2023 Phase 1
NCT05713292 Active not recruiting
COVID-19 Pneumonia
Capital Medical University
December 30 2022 Phase 3
NCT05505409 Recruiting
Pirfenidone|Connective Tissue Diseases|Interstitial Lung Disease
Qilu Hospital of Shandong University
June 22 2022 Phase 4

Preguntas frecuentes (Frequently Asked Questions)

Pregunta 1:
I'd like to know how to use your 50mg dose of it to make a solution for intraperitoneal injection in a mouse. Could you give me some advice?

Respuesta:
For I.P. injection, it can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve this compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water.